Similar articles

• Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.

  Satake K, Takeuchi T. Satake K, et al. Pancreas. 1994 Nov;9(6):720-4. doi: 10.1097/00006676-199411000-00008. Pancreas. 1994. PMID: 7846015
• Clinical relevance of serological markers in the detection and follow-up of pancreatic adenocarcinoma.

  Audisio RA, Veronesi P, Maisonneuve P, Chiappa A, Andreoni B, Bombardieri E, Geraghty JG. Audisio RA, et al. Surg Oncol. 1996 Apr;5(2):49-63. doi: 10.1016/s0960-7404(96)80001-6. Surg Oncol. 1996. PMID: 8853239 Review.
• Clinical evaluation of a new serum tumour marker CA 242 in pancreatic carcinoma.

  Pasanen PA, Eskelinen M, Partanen K, Pikkarainen P, Penttilä I, Alhava E. Pasanen PA, et al. Br J Cancer. 1992 May;65(5):731-4. doi: 10.1038/bjc.1992.154. Br J Cancer. 1992. PMID: 1316775 Free PMC article.
• [Tumor markers for detecting pancreatic cancer].

  Nakaizumi A, Tanaka S. Nakaizumi A, et al. Nihon Rinsho. 2006 Jan;64 Suppl 1:144-7. Nihon Rinsho. 2006. PMID: 16457238 Review. Japanese. No abstract available.
• [Tumor markers for pancreatic and biliary tract cancer].

  Takezako Y, Okusaka T, Ueno H, Ikeda M, Morizane C, Najima M. Takezako Y, et al. Gan To Kagaku Ryoho. 2004 Sep;31(9):1443-6. Gan To Kagaku Ryoho. 2004. PMID: 15446574 Review. Japanese.